Drug–microbiome–host interactions: antimicrobial effects of non-antibiotic compounds

Berg, G. et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome 8, 103 (2020).

Fan, Y. & Pedersen, O. Gut microbiota in human metabolic health and disease. Nat. Rev. Microbiol. 19, 55–71 (2021).

De Vos, W. M., Tilg, H., Van Hul, M. & Cani, P. D. Gut microbiome and health: mechanistic insights. Gut 71, 1020–1032 (2022).

Ferretti, P., Johnson, K., Priya, S. & Blekhman, R. Genomics of host–microbiome interactions in humans. Nat. Rev. Genet. 27, 62–80 (2026).

Zhernakova, D. V. et al. Host genetic regulation of human gut microbial structural variation. Nature 625, 813–821 (2024).

David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).

Ross, F. C. et al. The interplay between diet and the gut microbiome: implications for health and disease. Nat. Rev. Microbiol. 22, 671–686 (2024).

Sanz, Y. et al. The gut microbiome connects nutrition and human health. Nat. Rev. Gastroenterol. Hepatol. 22, 534–555 (2025).

Schumacher, J. et al. Proton-pump inhibitors increase C. difficile infection risk by altering pH rather than by affecting the gut microbiome based on a bioreactor model. Gut Microbes 17, 2519697 (2025).

Brinck, J. E. et al. Intestinal pH: a major driver of human gut microbiota composition and metabolism. Nat. Rev. Gastroenterol. Hepatol. 22, 639–656 (2025).

Vujkovic-Cvijin, I. et al. Host variables confound gut microbiota studies of human disease. Nature 587, 448–454 (2020).

Woelfel, S., Silva, M. S. & Stecher, B. Intestinal colonization resistance in the context of environmental, host, and microbial determinants. Cell Host Microbe 32, 820–836 (2024).

Zimmermann, M., Patil, K. R., Typas, A. & Maier, L. Towards a mechanistic understanding of reciprocal drug-microbiome interactions. Mol. Syst. Biol. 17, e10116 (2021).

Spanogiannopoulos, P., Bess, E. N., Carmody, R. N. & Turnbaugh, P. J. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat. Rev. Microbiol. 14, 273–287 (2016).

Weersma, R. K., Zhernakova, A. & Fu, J. Interaction between drugs and the gut microbiome. Gut 69, 1510–1519 (2020).

Gacesa, R. et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature 604, 732–739 (2022).

Nagata, N. et al. Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome. Gastroenterology 163, 1038–1052 (2022).

Aasmets, O. et al. A hidden confounder for microbiome studies: medications used years before sample collection. mSystems 10, e00541-25 (2025).

Hill, M. J. & Drasar, B. S. The normal colonic bacterial flora. Gut 16, 318–323 (1975).

Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).

Lindell, A. E., Zimmermann-Kogadeeva, M. & Patil, K. R. Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota. Nat. Rev. Microbiol. 20, 431–443 (2022).

Roux, I. et al. Industrial and agricultural chemicals exhibit antimicrobial activity against human gut bacteria in vitro. Nat. Microbiol. 10, 3107–3121 (2025).

Lindell, A. E. et al. Human gut bacteria bioaccumulate per- and polyfluoroalkyl substances. Nat. Microbiol. 10, 1630–1647 (2025).

Culp, E. J., Nelson, N. T., Verdegaal, A. A. & Goodman, A. L. Microbial transformation of dietary xenobiotics shapes gut microbiome composition. Cell 187, 6327–6345.e20 (2024).

Heirali, A., Moossavi, S., Arrieta, M. C. & Coburn, B. Principles and terminology for host–microbiome–drug interactions. Open. Forum Infect. Dis. 10, ofad195 (2023).

Zhao, Q., Chen, Y., Huang, W., Zhou, H. & Zhang, W. Drug-microbiota interactions: an emerging priority for precision medicine. Sig. Transduct. Target. Ther. 8, 386 (2023).

Trepka, K. R., Olson, C. A., Upadhyay, V., Zhang, C. & Turnbaugh, P. J. Pharma[e]cology: how the gut microbiome contributes to variations in drug response. Annu. Rev. Pharmacol. Toxicol. 65, 355–373 (2025).

Grießhammer, A. et al. Non-antibiotics disrupt colonization resistance against enteropathogens. Nature 644, 497–505 (2025).

Ricaurte, D. et al. High-throughput transcriptomics of 409 bacteria–drug pairs reveals drivers of gut microbiota perturbation. Nat. Microbiol. 9, 561–575 (2024).

Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 570, 462–467 (2019).

Klünemann, M. et al. Bioaccumulation of therapeutic drugs by human gut bacteria. Nature 597, 533–538 (2021).

Garcia-Santamarina, S. et al. Emergence of community behaviors in the gut microbiota upon drug treatment. Cell 187, 6346–6357.e20 (2024).

Kamrad, S., Davis, T. F. & Patil, K. R. Impact of drugs and environmental contaminants on amine production by gut bacteria. Mol. Syst. Biol. 21, 1351–1370 (2025).

Whelan, K., Bancil, A. S., Lindsay, J. O. & Chassaing, B. Ultra-processed foods and food additives in gut health and disease. Nat. Rev. Gastroenterol. Hepatol. 21, 406–427 (2024).

Gerasimidis, K. et al. The impact of food additives, artificial sweeteners and domestic hygiene products on the human gut microbiome and its fibre fermentation capacity. Eur. J. Nutr. 59, 3213–3230 (2020).

Blasche, S. et al. Common xenobiotics modulate gut microbial responses to low-calorie sweeteners in vitro. Mol. Syst. Biol.22, 1453–1473 (2026).

Chen, L. et al. Mapping pesticide-induced metabolic alterations in human gut bacteria. Nat. Commun. 16, 4355 (2025).

Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60 (2012).

Forslund, K. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262–266 (2015).

Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017).

Falony, G. et al. Population-level analysis of gut microbiome variation. Science 352, 560–564 (2016).

Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352, 565–569 (2016).

Vich Vila, A. et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun. 11, 362 (2020).

Forslund, S. K. et al. Combinatorial, additive and dose-dependent drug–microbiome associations. Nature 600, 500–505 (2021).

Larsson, A. et al. New connections of medication use and polypharmacy with the gut microbiota composition and functional potential in a large population. Sci. Rep. 14, 23723 (2024).

Le Bastard, Q., Berthelot, L., Soulillou, J.-P. & Montassier, E. Impact of non-antibiotic drugs on the human intestinal microbiome. Expert. Rev. Mol. Diagn. 21, 911–924 (2021).

Le Bastard, Q. et al. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment. Pharmacol. Ther. 47, 332–345 (2018).

Chassaing, B. et al. Randomized controlled-feeding study of dietary emulsifier carboxymethylcellulose reveals detrimental impacts on the gut microbiota and metabolome. Gastroenterology 162, 743–756 (2022).

Suez, J. et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514, 181–186 (2014).

Suez, J. et al. Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. Cell 185, 3307–3328.e19 (2022).

Serrano, J. et al. High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice. Microbiome 9, 11 (2021).

Ahmad, S. Y., Friel, J. & Mackay, D. The effects of non-nutritive artificial sweeteners, aspartame and sucralose, on the gut microbiome in healthy adults: secondary outcomes of a randomized double-blinded crossover clinical trial. Nutrients 12, 3408 (2020).

Thomson, P., Santibañez, R., Aguirre, C., Galgani, J. E. & Garrido, D. Short-term impact of sucralose consumption on the metabolic response and gut microbiome of healthy adults. Br. J. Nutr. 122, 856–862 (2019).

Matsuzaki, R. et al. Pesticide exposure and the microbiota–gut–brain axis. ISME J. 17, 1153–1166 (2023).

Giambò, F., Teodoro, M., Costa, C. & Fenga, C. Toxicology and microbiota: how do pesticides influence gut microbiota? A review. Int. J. Environ. Res. Public Health 18, 5510 (2021).

Sharma, T., Sirpu Natesh, N., Pothuraju, R., Batra, S. K. & Rachagani, S. Gut microbiota: a non-target victim of pesticide-induced toxicity. Gut Microbes 15, 2187578 (2023).

Meng, Z. et al. Gut microbiota: a key factor in the host health effects induced by pesticide exposure? J. Agric. Food Chem. 68, 10517–10531 (2020).

Gois, M. F. B. et al. Impact of occupational pesticide exposure on the human gut microbiome. Front. Microbiol. 14, 1223120 (2023).

De Filippis, F. et al. Exposure to environmental pollutants selects for xenobiotic-degrading functions in the human gut microbiome. Nat. Commun. 15, 4482 (2024).

Ueyama, J. et al. Effects of pesticide intake on gut microbiota and metabolites in healthy adults. Int. J. Environ. Res. Public Health 20, 213 (2023).

Zhang, K. et al. Ambient long-term exposure to organophosphorus pesticides and the human gut microbiome: an observational study. Environ. Health 23, 41 (2024).

Guillen, M. N., Li, C., Rosener, B. & Mitchell, A. Antibacterial activity of nonantibiotics is orthogonal to standard antibiotics. Science 384, 93–100 (2024).

Farha, M. A. et al. Antagonism screen for inhibitors of bacterial cell wall biogenesis uncovers an inhibitor of undecaprenyl diphosphate synthase. Proc. Natl Acad. Sci. USA 112, 11048–11053 (2015).

Meng, Q. et al. Repurposing benzbromarone as an antibacterial agent against Gram-positive bacteria. ACS Infect. Dis. 10, 4208–4221 (2024).

Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 415, 389–395 (2002).

Caldara, M. & Marmiroli, N. Antimicrobial properties of antidepressants and antipsychotics — possibilities and implications. Pharmaceuticals 14, 915 (2021).

Lu, J., Ding, P., Wang, Y. & Guo, J. Antidepressants promote the spread of extracellular antibiotic resistance genes via transformation. ISME Commun. 2, 63 (2022).

Blaskovich, M. A. T. et al. The antimicrobial potential of cannabidiol. Commun. Biol. 4, 7 (2021).

Fitzgerald, D. J. et al. Mode of antimicrobial action of vanillin against Escherichia coli, Lactobacillus plantarum and Listeria innocua. J. Appl. Microbiol. 97, 104–113 (2004).

Panella, M. et al. Membrane-modifying effects of perfluoroalkyl substances in model bacterial membranes. ACS Omega 10, 39884–39897 (2025).

Yin, Z. et al. DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem. Biol. 21, 481–487 (2014).

LaCourse, K. D. et al. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota. Cell Rep. 41, 111625 (2022).

Spanogiannopoulos, P. et al. Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism. Nat. Microbiol. 7, 1605–1620 (2022).

de Dios, R. et al. Saccharin disrupts bacterial cell envelope stability and interferes with DNA replication dynamics. EMBO Mol. Med. 17, 993–1017 (2025).

Lo, Y.-S., Tseng, W.-H., Chuang, C.-Y. & Hou, M.-H. The structural basis of actinomycin D-binding induces nucleotide flipping out, a sharp bend and a left-handed twist in CGG triplet repeats. Nucleic Acids Res. 41, 4284–4294 (2013).

Aviner, R. The science of puromycin: from studies of ribosome function to applications in biotechnology. Computat. Struct. Biotechnol. J. 18, 1074–1083 (2020).

Zhao, Y., Xu, C., Chen, X., Jin, H. & Li, H. Structural basis for hygromycin B inhibition of yeast pseudouridine-deficient ribosomes. Sci. Adv. 11, eadu0151 (2025).

Powers, K. T. et al. Blasticidin S inhibits mammalian translation and enhances production of protein encoded by nonsense mRNA. Nucleic Acids Res. 49, 7665–7679 (2021).

Miller, M. & Singer, M. Do antibiotics cause mitochondrial and immune cell dysfunction? A literature review. J. Antimicrob. Chemother. 77, 1218–1227 (2022).

Nayak, R. R. et al. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation. Cell Host Microbe 29, 362–377.e11 (2021).

Walsh, L., Hill, C. & Ross, R. P. Impact of glyphosate (Roundup) on the composition and functionality of the gut microbiome. Gut Microbes 15, 2263935 (2023).

Bose, S. et al. Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor. Commun. Biol. 6, 360 (2023).

Yilmaz, E. Orlistat-induced molecular bio-imprinting of microbial lipase. World J. Microbiol. Biotechnol. 19, 161–165 (2003).

Uehira, Y. et al. Impact of the lipase inhibitor orlistat on the human gut microbiota. Obes. Res. Clin. Pract. 17, 411–420 (2023).

Brown, H. A. et al. Acarbose impairs gut Bacteroides growth by targeting intracellular glucosidases. mBio 15, e01506-24 (2024).

Fung, T. C. et al. Intestinal serotonin and fluoxetine exposure modulate bacterial colonization in the gut. Nat. Microbiol. 4, 2064–2073 (2019).

Bohnert, J. A., Szymaniak-Vits, M., Schuster, S. & Kern, W. V. Efflux inhibition by selective serotonin reuptake inhibitors in Escherichia coli. J. Antimicrob. Chemother. 66, 2057–2060 (2011).

de la Cuesta-Zuluaga, J., Boldt, L. & Maier, L. Response, resistance, and recovery of gut bacteria to human-targeted drug exposure. Cell Host Microbe 32, 786–793 (2024).

Bouillet, S., Bauer, T. S. & Gottesman, S. RpoS and the bacterial general stress response. Microbiol. Mol. Biol. Rev. 88, e00151-22 (2024).

Pandya, C., Farelli, J. D., Dunaway-Mariano, D. & Allen, K. N. Enzyme promiscuity: engine of evolutionary innovation. J. Biol. Chem. 289, 30229–30236 (2014).

Li, L. et al. RapidAIM: a culture- and metaproteomics-based rapid assay of individual microbiome responses to drugs. Microbiome 8, 33 (2020).

Jackson, M. A. et al. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat. Commun. 9, 2655 (2018).

Freedberg, D. E., Lebwohl, B. & Abrams, J. A. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin. Lab. Med. 34, 771–785 (2014).

Caparrós-Martín, J. A. et al. Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome 5, 95 (2017).

Huang, E. Y. et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm. Bowel Dis. 21, 963–972 (2015).

Okafuji, H. et al. Oral corticosteroids impair mucin production and alter the posttransplantation microbiota in the gut. Digestion 103, 269–286 (2022).

Pereira, F. C. et al. The Parkinson’s disease drug entacapone disrupts gut microbiome homeostasis via iron sequestration. Nat. Microbiol. 9, 3165–3183 (2024).

Kumar, A. et al. Identification of medication-microbiome interactions that affect gut infection. Nature 644, 506–515 (2025).

Kralj, T. et al. Multi-omic analysis to characterize metabolic adaptation of the E. coli lipidome in response to environmental stress. Metabolites 12, 171 (2022).

Moon, S. et al. Temperature matters: bacterial response to temperature change. J. Microbiol. 61, 343–357 (2023).

Huus, K. E. & Ley, R. E. Blowing hot and cold: body temperature and the microbiome. mSystems 6, e00707-21 (2021).

Huys, G., D’Haene, K. & Swings, J. Influence of the culture medium on antibiotic susceptibility testing of food-associated lactic acid bacteria with the agar overlay disc diffusion method. Lett. Appl. Microbiol. 34, 402–406 (2002).

Joly Condette, C. et al. Effect of daily co-exposure to inulin and chlorpyrifos on selected microbiota endpoints in the SHIME model. Environ. Pollut. 302, 118961 (2022).

Nguyen, D. et al. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 334, 982–986 (2011).

McCallum, G. & Tropini, C. The gut microbiota and its biogeography. Nat. Rev. Microbiol. 22, 105–118 (2024).

van den Berg, N. I. et al. Emergent survival and extinction of species within gut bacterial communities. Preprint at bioRxiv https://doi.org/10.1101/2024.04.29.591619 (2024).

Shi, H. et al. Nutrient competition predicts gut microbiome restructuring under drug perturbations. Cell 188, 6971–6986.e14 (2025).

Kamrad, S. et al. Interspecies interactions drive bacterial proteome reorganization and emergent metabolism. Nat. Ecol. Evol. 10, 1127–1144 (2026).

Kamrad, S. et al. Metabolic heterogeneity and cross-feeding within isogenic yeast populations captured by DILAC. Nat. Microbiol. 8, 441–454 (2023).

Wolfson, S. J. et al. Bacterial hydrogen sulfide drives cryptic redox chemistry in gut microbial communities. Nat. Metab. 4, 1260–1270 (2022).

Javdan, B. et al. Personalized mapping of drug metabolism by the human gut microbiome. Cell 181, 1661–1679.e22 (2020).

Gomez Lumbreras, A. et al. Shared decision-making for drug–drug interactions: formative evaluation of an anticoagulant drug interaction. J. Med. Internet Res. Form. Res. 6, e40018 (2022).

Bailey, D. G., Dresser, G. & Arnold, J. M. O. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? Can. Med. Assoc. J. 185, 309–316 (2013).

Brochado, A. R. et al. Species-specific activity of antibacterial drug combinations. Nature 559, 259–263 (2018).

Martino, C. et al. Microbiota succession throughout life from cradle to the grave. Nat. Rev. Microbiol. 20, 707–720 (2022).

Choi, H., Rao, M. C. & Chang, E. B. Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism. Nat. Rev. Gastroenterol. Hepatol. 18, 679–689 (2021).

Zommiti, M. & Feuilloley, M. G. J. Sex hormones–gut microbiome axis: an update of what is known so far. Curr. Opin. Endocr. Metab. Res. 38, 100571 (2025).

Besten, G. et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325–2340 (2013).

Urdaneta, V. & Casadesús, J. Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts. Front. Med. 4, 163 (2017).

Malik, U. et al. Association between prior antibiotic therapy and subsequent risk of community-acquired infections: a systematic review. J. Antimicrob. Chemother. 73, 287–296 (2018).

Miller, A. C. et al. Comparison of different antibiotics and the risk for community-associated Clostridioides difficile infection: a case–control study. Open. Forum Infect. Dis. 10, ofad413 (2023).

Fishbein, S. R. S., Mahmud, B. & Dantas, G. Antibiotic perturbations to the gut microbiome. Nat. Rev. Microbiol. 21, 772–788 (2023).

de Nies, L., Kobras, C. M. & Stracy, M. Antibiotic-induced collateral damage to the microbiota and associated infections. Nat. Rev. Microbiol. 21, 789–804 (2023).

Huang, H., Jiang, J., Wang, X., Jiang, K. & Cao, H. Exposure to prescribed medication in early life and impacts on gut microbiota and disease development. eClinicalMedicine 68, 102428 (2024).

She, J. et al. Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner. Cell Metab. 36, 408–421.e5 (2024).

Bretler, T., Weisberg, H., Koren, O. & Neuman, H. The effects of antipsychotic medications on microbiome and weight gain in children and adolescents. BMC Med. 17, 112 (2019).

Michaelis, L., Berg, L. & Maier, L. Confounder or confederate? The interactions between drugs and the gut microbiome in psychiatric and neurological diseases. Biol. Psychiatry 95, 361–369 (2023).

Simpson, J. B. et al. Gut microbial β-glucuronidases influence endobiotic homeostasis and are modulated by diverse therapeutics. Cell Host Microbe 32, 925–944.e10 (2024).

Vieira-Silva, S. et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature 581, 310–315 (2020).

Rosell-Díaz, M. & Fernández-Real, J. M. Metformin, cognitive function, and changes in the gut microbiome. Endocr. Rev. 45, 210–226 (2024).

Koppel, N., Bisanz, J. E., Pandelia, M.-E., Turnbaugh, P. J. & Balskus, E. P. Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins. eLife 7, e33953 (2018).

Haiser, H. J. et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium eggerthella lenta. Science 341, 295–298 (2013).

Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010).

Wallace, B. D. et al. Structure and inhibition of microbiome β-glucuronidases essential to the alleviation of cancer drug toxicity. Chem. Biol. 22, 1238–1249 (2015).

van Kessel, S. P. et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat. Commun. 10, 310 (2019).

Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J. & Balskus, E. P. Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. Science 364, eaau6323 (2019).

Zhang, Y. et al. Association between microbial tyrosine decarboxylase gene and levodopa responsiveness in patients with Parkinson disease. Neurology 99, e2443–e2453 (2022).

Tian, J. et al. Inactivation of the antidiabetic drug acarbose by human intestinal microbial-mediated degradation. Nat. Metab. 5, 896–909 (2023).

Balaich, J. et al. The human microbiome encodes resistance to the antidiabetic drug acarbose. Nature 600, 110–115 (2021).

Alam, Y. et al. Variation in human gut microbiota impacts tamoxifen pharmacokinetics. mBio 16, e01679-24 (2024).

Mehta, R. S. et al. Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease. Nat. Med. 29, 700–709 (2023).

Roje, B. et al. Gut microbiota carcinogen metabolism causes distal tissue tumours. Nature 632, 1137–1144 (2024).

Meng, J. et al. Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model. Br. J. Pharmacol. 180, 1362–1378 (2023).

Mager, L. F., Krause, T. & McCoy, K. D. Interaction of microbiota, mucosal malignancies, and immunotherapy — mechanistic insights. Mucosal Immunol. 17, 402–415 (2024).

Vétizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).

Mager, L. F. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369, 1481–1489 (2020).

He, Y. et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity. Cell Metab. 33, 988–1000.e7 (2021).

Tintelnot, J. et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168–174 (2023).

Bolte, L. A., Björk, J. R., Gacesa, R. & Weersma, R. K. Pharmacomicrobiomics: the role of the gut microbiome in immunomodulation and cancer therapy. Gastroenterology 169, 813–827 (2025).

Nguyen, C. L. et al. High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients. Cell 186, 2705–2718.e17 (2023).

Kyono, Y. et al. The atypical antipsychotic quetiapine promotes multiple antibiotic resistance in Escherichia coli. J. Bacteriol. 204, e00102–e00122 (2022).

Ou, J. et al. TCA and SSRI antidepressants exert selection pressure for efflux-dependent antibiotic resistance mechanisms in Escherichia coli. mBio 13, e02191-22 (2022).

Wang, Y. et al. Antidepressants can induce mutation and enhance persistence toward multiple antibiotics. Proc. Natl Acad. Sci. USA 120, e2208344120 (2023).

Dop, C., Auvin, S., Mondot, S., Lepage, P. & Ilhan, Z. E. Longitudinal exposure to antiseizure medications shape gut-derived microbiome, resistome, and metabolome landscape. ISME Commun. 4, ycae123 (2024).

Kyono, Y., Magboo, J. D., Daley, E. A. & Flowers, S. A. Antipsychotic quetiapine alters the mouse fecal resistome by impacting antibiotic efflux, cell membrane, and cell wall synthesis genes. Microbiol. Spectr. 12, e03804–e03823 (2023).

Wang, Y. et al. Non-antibiotic pharmaceuticals promote conjugative plasmid transfer at a community-wide level. Microbiome 10, 124 (2022).

Alav, I. & Buckner, M. M. C. Non-antibiotic compounds associated with humans and the environment can promote horizontal transfer of antimicrobial resistance genes. Crit. Rev. Microbiol. 50, 993–1010 (2024).

Ding, P., Lu, J., Wang, Y., Schembri, M. A. & Guo, J. Antidepressants promote the spread of antibiotic resistance via horizontally conjugative gene transfer. Environ. Microbiol. 24, 5261–5276 (2022).

Ding, P. et al. Antidepressant drugs promote the spread of broad-host-range plasmid in mouse and human gut microbiota. Gut Microbes 17, 2514138 (2025).

Wang, Y. et al. Antiepileptic drug carbamazepine promotes horizontal transfer of plasmid-borne multi-antibiotic resistance genes within and across bacterial genera. ISME J. 13, 509–522 (2019).

Yu, Z., Henderson, I. R. & Guo, J. Non-caloric artificial sweeteners modulate conjugative transfer of multi-drug resistance plasmid in the gut microbiota. Gut Microbes 15, 2157698 (2023).

Domenech, A. et al. Proton motive force disruptors block bacterial competence and horizontal gene transfer. Cell Host Microbe 27, 544–555.e3 (2020).

Kim, C. Y. et al. Planetary microbiome structure and generalist-driven gene flow across disparate habitats. Cell 189, 2073–2091.e21 (2026).

Aasmets, O., Krigul, K. L., Lüll, K., Metspalu, A. & Org, E. Gut metagenome associations with extensive digital health data in a volunteer-based Estonian microbiome cohort. Nat. Commun. 13, 869 (2022).

Petersen, K. & Mansell, T. J. Unveiling the prebiotic potential of polyphenols in gut health and metabolism. Curr. Opin. Biotechnol. 95, 103338 (2025).

Tropini, C. et al. Transient osmotic perturbation causes long-term alteration to the gut microbiota. Cell 173, 1742–1754.e17 (2018).

Clayton, C. A. et al. In mouse and in vitro models, bowel preparation promotes pathogen colonization, translocation, and exacerbation of inflammation. Cell Rep. Med. 7, 102517 (2025).

Jo, H. H., Lee, M. Y., Ha, S. E., Yeom, D. H. & Kim, Y. S. Alteration in gut microbiota after colonoscopy: proposed mechanisms and the role of probiotic interventions. Clin. Endosc. 58, 25–39 (2024).

Cruz-Lebrón, A. et al. Chronic opioid use modulates human enteric microbiota and intestinal barrier integrity. Gut Microbes 13, 1946368 (2021).

Gicquelais, R. E., Bohnert, A. S. B., Thomas, L. & Foxman, B. Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment. Sci. Rep. 10, 19471 (2020).

Lopez-Moreno, A. et al. Bisphenol A exposure affects specific gut taxa and drives microbiota dynamics in childhood obesity. mSystems 9, e00957-23 (2024).

Lear, G. et al. Plastics and the microbiome: impacts and solutions. Environ. Microbiome 16, 2 (2021).

Hillege, L. E. et al. Metagenomic analysis during capecitabine therapy reveals microbial chemoprotective mechanisms and predicts drug toxicity in colorectal cancer patients. Preprint at medRxiv https://doi.org/10.1101/2024.10.11.24315249 (2024).

Naimi, S., Viennois, E., Gewirtz, A. T. & Chassaing, B. Direct impact of commonly used dietary emulsifiers on human gut microbiota. Microbiome 9, 66 (2021).

Chassaing, B., Van de Wiele, T., De Bodt, J., Marzorati, M. & Gewirtz, A. T. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut 66, 1414–1427 (2017).

Qiao, J. et al. Specific enterotype of gut microbiota predicted clinical effect of methotrexate in patients with rheumatoid arthritis. Rheumatology 62, 1087–1096 (2023).

Villa Soto, V. S. et al. The gut microbiome shapes pharmacology and treatment outcomes for a key anti-inflammatory therapy. Preprint at bioRxiv https://doi.org/10.1101/2025.06.26.661733 (2025).

Bhattacharya, R. & Beck, D. J. Survival and SOS induction in cisplatin-treated Escherichia coli deficient in Pol II, RecBCD and RecFOR functions. DNA Repair 1, 955–966 (2002).

Joyce, K. et al. Antimicrobial spectrum of the antitumor agent, cisplatin. J. Antibiot. 63, 530–532 (2010).

Gong, S. et al. Gut microbiota accelerates cisplatin-induced acute liver injury associated with robust inflammation and oxidative stress in mice. J. Transl. Med. 19, 147 (2021).

Tian, L. et al. Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota. Front. Pharmacol. 14, 1217306 (2023).

Beliaeva, M. A., Wilmanns, M. & Zimmermann, M. Decipher enzymes from human microbiota for drug discovery and development. Curr. Opin. Struct. Biol. 80, 102567 (2023).

Periwal, V. et al. Bioactivity assessment of natural compounds using machine learning models trained on target similarity between drugs. PLoS Comput. Biol. 18, e1010029 (2022).

Guthrie, L., Wolfson, S. & Kelly, L. The human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs. eLife 8, e42866 (2019).

Klünemann, M., Schmid, M. & Patil, K. R. Computational tools for modeling xenometabolism of the human gut microbiota. Trends Biotechnol. 32, 157–165 (2014).

Heinken, A. et al. Genome-scale metabolic reconstruction of 7,302 human microorganisms for personalized medicine. Nat. Biotechnol. 41, 1320–1331 (2023).

Müller, P. et al. High-throughput anaerobic screening for identifying compounds acting against gut bacteria in monocultures or communities. Nat. Protoc. 19, 668–699 (2024).

Aranda-Díaz, A. et al. Establishment and characterization of stable, diverse, fecal-derived in vitro microbial communities that model the intestinal microbiota. Cell Host Microbe 30, 260–272.e5 (2022).

Zünd, J. N. et al. A flexible high-throughput cultivation protocol to assess the response of individuals’ gut microbiota to diet-, drug-, and host-related factors. ISME Commun. 4, ycae035 (2024).

El Houari, A. et al. Development of an in vitro model of human gut microbiota for screening the reciprocal interactions with antibiotics, drugs, and xenobiotics. Front. Microbiol. 13, 828359 (2022).

Cacace, E., Kritikos, G. & Typas, A. Chemical genetics in drug discovery. Curr. Opin. Syst. Biol. 4, 35–42 (2017).

Liu, H. et al. Functional genetics of human gut commensal Bacteroides thetaiotaomicron reveals metabolic requirements for growth across environments. Cell Rep. 34, 108789 (2021).

Wuyts, S. et al. Consistency across multi-omics layers in a drug-perturbed gut microbial community. Mol. Syst. Biol. 19, e11525 (2023).

Zampieri, M. et al. High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds. Sci. Transl. Med. 10, eaal3973 (2018).

Malinovska, L. et al. Proteome-wide structural changes measured with limited proteolysis-mass spectrometry: an advanced protocol for high-throughput applications. Nat. Protoc. 18, 659–682 (2023).